Ads
related to: methylprednisolone infusion protocol for diabetes 1 and 2 and 3 and 4- Clinical Data
Clinical Trial Data Presented For
US Healthcare Professionals.
- Safety Data
Safety Info & Side Effects Data For
US Healthcare Professionals.
- Dosing Data
Dosing Considerations And Data For
US Healthcare Professionals.
- Patient Coverage
With co-pay options available
Search for patient coverage.
- Clinical Data
Search results
Results from the WOW.Com Content Network
The first patient was treated using the Edmonton protocol in March 1999. The protocol was first published in the New England Journal of Medicine in July 2000. [1] The NEJM report was exciting for the diabetes field because the seven patients undergoing the Edmonton protocol remained insulin-independent after an average of 12 months. [citation ...
Oral methylprednisolone has a moderate distribution into tissue at 1.38L/kg. [39] Methylprednisolone is primarily eliminated by hepatic metabolism and renal excretion of metabolites; with renal excretion of unchanged methylprednisolone at only 1.3–9.2%. [39] Methylprednisolone can be interconverted with methylprednisone. [32]
[1] [4] [5] Methylprednisolone acetate was previously suspended with polyethylene glycol but is no longer formulated with this excipient due to concerns about possible toxicity. [6] [8] Depo methylprednisolone acetate is a depot injection and is absorbed slowly with a duration of weeks to months with a single intramuscular injection. [5]
[3] [4] Methylprednisolone succinate is provided as two different salts when used as a pharmaceutical drug: a sodium salt (methylprednisolone sodium succinate; brand name Solu-Medrol, others) and a hydrogen salt (methylprednisolone hemisuccinate or methylprednisolone hydrogen succinate; brand name Urbason). [3] [4]
Subcutaneous infusion, also known as interstitial infusion or hypodermoclysis, is a form of subcutaneous (under the skin) administration of fluids to the body, often saline or glucose solutions. [26] It is the infusion counterpart of subcutaneous injection with a syringe.
Prednisolone has a relatively short half-life, ranging 2–4 hours. It also has a large therapeutic window , considering the dosage required to produce a therapeutic effect is a few times higher than what the body naturally produces.
The hyperglycemic clamp, which requires maintaining a high blood sugar level by perfusion or infusion with glucose, is a way to quantify how fast beta-cells respond to glucose. The hyperinsulinemic clamp, which requires maintaining a high insulin level by perfusion or infusion with insulin, is a way to quantify how sensitive the tissue is to ...
Methylprednisolone aceponate, or methylprednisolone acetate propionate, sold under the brand names Advantan and Avancort, is a glucocorticoid and a corticosteroid ester—specifically the C17α propionate and C21 acetate diester of methylprednisolone. [2] [3] [4]
Ads
related to: methylprednisolone infusion protocol for diabetes 1 and 2 and 3 and 4